Diagnosis of carcinoma of unknown primary site with the aid of simple PCR tests: a single-center experience

Suspitsin, Evgeny N.; Yanus, Grigoriy A.; Imyanitov, Evgeny N.

doi:10.4149/neo_2018_170423n304

Cited by 1 publication

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The spectrum of diagnostic antibodies is restricted to the ones marketed by biotech companies. Finally, interpretation of IHC results is a subject of interlaboratory variations (Pavlidis and Fizazi, 2009; Massard et al, 2011; Economopoulou et al, 2015; Suspitsin et al, 2018). …”

Section: The Diagnosis Of Cancers Of Unknown Primary Sitementioning

confidence: 99%

“…Finally, PCR assays can be performed and interpreted in a semi-automated manner. Many studies demonstrate the utility of DNA/RNA analysis for determination of CUP origin (Talantov et al, 2006; Greco et al, 2010; Suspitsin et al, 2018). It is likely that NGS will provide more opportunities for CUP diagnosis in the near future (Varghese et al, 2017).…”

Section: The Diagnosis Of Cancers Of Unknown Primary Sitementioning

confidence: 99%

See 1 more Smart Citation

Molecular Diagnostics in Clinical Oncology

Sokolenko

Imyanitov

2018

Front. Mol. Biosci.

109

View full text Add to dashboard Cite

There are multiple applications of molecular tests in clinical oncology. Mutation analysis is now routinely utilized for the diagnosis of hereditary cancer syndromes. Healthy carriers of cancer-predisposing mutations benefit from tight medical surveillance and various preventive interventions. Cancers caused by germ-line mutations often require significant modification of the treatment strategy. Personalized selection of cancer drugs based on the presence of actionable mutations has become an integral part of cancer therapy. Molecular tests underlie the administration of EGFR, BRAF, ALK, ROS1, PARP inhibitors as well as the use of some other cytotoxic and targeted drugs. Tumors almost always shed their fragments (single cells or their clusters, DNA, RNA, proteins) into various body fluids. So-called liquid biopsy, i.e., the analysis of circulating DNA or some other tumor-derived molecules, holds a great promise for non-invasive monitoring of cancer disease, analysis of drug-sensitizing mutations and early cancer detection. Some tumor- or tissue-specific mutations and expression markers can be efficiently utilized for the diagnosis of cancers of unknown primary origin (CUPs). Systematic cataloging of tumor molecular portraits is likely to uncover a multitude of novel medically relevant DNA- and RNA-based markers.

show abstract